Overview of the Partnership
Viz.ai, a leader in AI-driven imaging and care coordination, has announced a collaboration with Novartis to create specialized AI workflows within the Viz Oncology Suite.
Key Features of the Viz Oncology Suite
- Includes over 50 FDA-cleared algorithms for analyzing medical imaging data.
- Aims to enhance diagnosis, streamline workflows, and support treatment decisions.
Focus Areas of the Collaboration
The partnership will concentrate on:
- Improving identification and stratification of patients with prostate and breast cancers.
- Accelerating access to guideline-based precision treatments.
- Reducing delays in diagnosis and treatment through coordinated care.
New AI Offerings
Viz.ai plans to introduce two new AI solutions:
- Viz Prostate Cancer: Identifies eligible patients for guideline-based treatment and facilitates referrals to specialists.
- Viz Breast Cancer: Assists breast oncologists by automating patient reviews and aggregating relevant risk data.
Statements from Leadership
Dr. Chris Mansi, CEO and co-founder of Viz.ai, expressed enthusiasm about the partnership, stating, “We are excited to be partnering with Novartis, a leader in oncology, to enhance access to timely, guideline-based care for patients with prostate and breast cancer.”
Industry Context
This collaboration is part of a broader trend in healthcare where AI is increasingly utilized to improve patient outcomes. Recent partnerships include:
- A collaboration with Regeneron and Sanofi to develop an AI-enabled workflow tool for COPD management.
- A multi-year agreement with Bristol Myers Squibb to release an AI algorithm for hypertrophic cardiomyopathy.
- A partnership with Dawn Health to create a chronic condition management platform.
Conclusion
The collaboration between Viz.ai and Novartis represents a significant step towards enhancing cancer care through AI, aiming to streamline processes and improve patient outcomes in oncology.
